RCKT - Rocket Pharmaceuticals' Phase 2 Trial Design for RP-A501 in Danon Disease Reaches FDA Alignment
2023-09-13 09:14:10 ET
(24/7 MARKET NEWS) – Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) stated, after yesterday’s market close, that it reached alignment with the Food and Drug Administration (FDA) on the global Phase 2 pivotal trial of RP-A501 for Danon Disease, a uniformly fatal inherited cardiomyopathy that leads to mortality in the majority of male patients at age ~20 and females at age ~40, and for which there are no approved curative or disease-modifying therapies. The disease affects an estimated 15,000 to 30,000 patients in the U.S. and Europe.
Rocket Pharmaceuticals further announced, this morning, that it priced an underwritten public offering of (i) 7,812,500 shares of its common stock at a public offering price of $16.00 per share and (ii) to certain investors, pre-funded …
The post Rocket Pharmaceuticals’ Phase 2 Trial Design for RP-A501 in Danon Disease Reaches FDA Alignment appeared first on 24/7 Market News .
For further details see:
Rocket Pharmaceuticals’ Phase 2 Trial Design for RP-A501 in Danon Disease Reaches FDA Alignment